Case in point, when Doja Cat literally bit into a tube of MAC lipstick at the MTV VMAs, it drove $2.8 million in media impact value, per Launchmetrics
Monitoring energy, dizziness, nausea, or dehydration symptoms
Retatrutide (LY3437943) is a synthetic peptide analog designed as a triple hormone receptor agonist, targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.[1][2] It has a molecular weight of approximately 4,800 Da and is administered subcutaneously, with a half-life supporting once-weekly dosing.[3][4] Developed by Eli Lilly, it is currently in Phase 3 clinical trials for obesity and type 2 diabetes (T2D), showing potential for superior weight loss compared to existing therapies.[1][5] Key characteristics for compounding pharmacies include: Multi-Receptor Agonist : Combines actions of GIP, GLP-1, and glucagon for enhanced metabolic effects.[1][6] Lyophilized Form : Supplied as a stable powder for reconstitution, similar to other peptides.[7][8] Versatile Delivery : Primarily subcutaneous, but potential for customized formulations in research contexts.[7][9] This makes Retatrutide a candidate for specialized preparations in compounding settings, though regulatory restrictions apply
The analysis found no significant association between specific GLP-1 RAs and androgenetic alopecia, though semaglutide showed a potential trend toward increased hair loss
doi: 10.1016/S0006-291X(72)80218-3 50
